ImmunoCellular Therapeutics, Ltd Appoints Gary S. Titus to its Board of Directors
1/2/2013 6:17:46 AM
ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) today announced the appointment of Gary S. Titus to its board of directors. Mr. Titus is currently the Senior Vice President and Chief Financial Officer of SciClone Pharmaceuticals, Inc. and has more than 20 years of business experience in the healthcare and biopharmaceutical industries. Mr. Titus has extensive experience in working with public corporations in a variety of areas, including financial planning and analysis, SEC reporting, investor relations, business development, and corporate strategy.